Change

Consolidated statement of income


 

In € millions

 

 

 

2000

2001

2002

20031

2004

20052

2006

2007

2008

2009

1

The 2000 – 2003 figures have not been restated to IFRS accounting standards. The differences mainly relate to pensions and other post-retirement benefits, the recognition of deferred taxes on intercompany profit, and the recognition of goodwill. For the most part, the changed accounting is a matter of timing of the recognition of the assets, liabilities and related results.

2

The 2000 – 2005 figures have not been restated for the Organon BioSciences divestment.

3

Not meaningful as operating income was a loss.

 

 

 

 

 

 

 

 

 

 

 

Revenue

14,069

14,158

14,059

13,106

12,833

13,000

10,023

10,217

15,415

13,893

Operating income

1,440

1,162

1,390

1,146

1,588

1,492

887

778

(577)

870

Financing income and expenses

(198)

(221)

(232)

(248)

(205)

(162)

(134)

(151)

(232)

(409)

Income tax

(395)

(294)

(335)

(254)

(412)

(338)

(96)

(166)

(260)

(128)

Results from associates and joint ventures

143

55

30

7

10

6

87

(20)

25

22

Profit for the period from continuing operations

990

702

853

651

981

998

744

441

(1,044)

355

 

 

 

 

 

 

 

 

 

 

 

Minority interests attributable to minority shareholders

(43)

(31)

(35)

(49)

(36)

(37)

(29)

(31)

(65)

(77)

Discontinued operations

438

8,920

23

7

Net income, attributable to shareholders

947

671

818

602

945

961

1,153

9,330

(1,086)

285

 

 

 

 

 

 

 

 

 

 

 

Common shares,
in millions at year-end

285.9

285.9

285.7

285.7

285.8

285.8

287.0

262.3

231.7

232.3

Dividend

343.0

343.0

343.0

343.0

343.0

343.0

344.0

472.0

417.0

325.2

 

 

 

 

 

 

 

 

 

 

 

Number of employees at year-end

68,400

66,300

67,900

64,600

61,400

61,300

42,700

42,600

60,000

57,100

Salaries, wages, and other employee benefits

3,285

3,416

3,552

3,505

3,216

3,221

2,158

2,215

3,022

2,944

Salaries, wages, and other employee benefits in percent of revenue

23.3

24.1

25.3

26.7

25.1

24.8

21.5

21.7

19.6

21.2

 

 

 

 

 

 

 

 

 

 

 

Ratios

 

 

 

 

 

 

 

 

 

 

Operating income in percent of revenue

10.2

8.2

9.9

8.7

12.4

11.5

8.8

7.6

(3.7)

6.3

Operating income in percent of invested capital

16.2

12.5

15.4

13.6

20.8

19.4

16.3

14.6

3

6.5

Net income in percent of shareholders’ equity

39.7

24.1

32.9

26.2

40.6

32.0

30.5

122.9

3

3.7

 

 

 

 

 

 

 

 

 

 

 

Interest coverage

7.3

5.3

6.0

4.6

7.7

9.2

6.6

5.2

3

2.1

EBITDA coverage

10.6

8.3

8.9

7.3

10.5

12.7

9.4

7.5

3

4.3

 

 

 

 

 

 

 

 

 

 

 

Per share information

 

 

 

 

 

 

 

 

 

 

Net income

3.31

2.35

2.86

2.11

3.31

3.36

4.02

33.82

(4.38)

1.23

Dividend

1.20

1.20

1.20

1.20

1.20

1.20

1.20

1.80

1.80

1.35

Shareholders’ equity

9.42

10.07

7.34

8.76

9.12

11.95

14.44

42.06

32.21

33.48

 

 

 

 

 

 

 

 

 

 

 

Highest share price during the year

59.15

57.85

54.50

32.44

33.79

40.18

49.41

65.56

57.11

46.52

Lowest share price during the year

37.30

33.73

27.25

16.00

24.87

30.82

38.30

44.41

22.85

26.01

Year-end share price

57.20

50.15

30.23

30.60

31.38

39.15

46.18

54.79

29.44

46.40

For definitions of certain financial ratios and concepts see the full glossary.

Keyword Search
Copyright © 2010 Akzo Nobel N.V.